Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials

In 2014 and 2021, two nucleic-acid vaccine candidates named MAV E2 and VGX-3100 completed phase III clinical trials in Mexico and U.S., respectively, for patients with human papillomavirus (HPV)-related, high-grade squamous intraepithelial lesions (HSIL). These well-tolerated but still unlicensed va...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jianming, Li, Mingzhu, Zhao, Chao, Shen, Danhua, Liu, Lei, Zhang, Xiujun, Wei, Lihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874761/
https://www.ncbi.nlm.nih.gov/pubmed/35215833
http://dx.doi.org/10.3390/v14020239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874761/
https://www.ncbi.nlm.nih.gov/pubmed/35215833
http://dx.doi.org/10.3390/v14020239

Ejemplares similares